A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Ozanimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Receptos
- 08 May 2017 Planned End Date changed from 25 Dec 2020 to 30 Sep 2020.
- 20 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 27 Aug 2015 New trial record